BIO report makes case for 14 years of biosimilar exclusivity
This article was originally published in Scrip
Executive Summary
US biosimilars legislation with less than 14 years of innovator data exclusivity would give the federal government little additional cost savings, but would spur a drop in biotechnology R&D by at least $41 billion, a new report commissioned by the trade group BIOsays.